BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32532234)

  • 21. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
    Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
    Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M
    Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data.
    Bejon P; White MT; Olotu A; Bojang K; Lusingu JP; Salim N; Otsyula NN; Agnandji ST; Asante KP; Owusu-Agyei S; Abdulla S; Ghani AC
    Lancet Infect Dis; 2013 Apr; 13(4):319-27. PubMed ID: 23454164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models.
    Penny MA; Verity R; Bever CA; Sauboin C; Galactionova K; Flasche S; White MT; Wenger EA; Van de Velde N; Pemberton-Ross P; Griffin JT; Smith TA; Eckhoff PA; Muhib F; Jit M; Ghani AC
    Lancet; 2016 Jan; 387(10016):367-375. PubMed ID: 26549466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi.
    Khan S; Parrillo M; Gutierrez AH; Terry FE; Moise L; Martin WD; De Groot AS
    Hum Vaccin Immunother; 2020; 16(2):214-227. PubMed ID: 30614773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
    Agnandji ST; Fernandes JF; Bache EB; Ramharter M
    Future Microbiol; 2015; 10(10):1553-78. PubMed ID: 26437872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Immunogenicity of Seven Dosing Regimens of the Candidate RTS,S/AS01E Malaria Vaccine Integrated Within an Expanded Program on Immunization Regimen: A Phase II, Single-Center, Open, Controlled Trial in Infants in Malawi.
    Witte D; Cunliffe NA; Turner AM; Ngulube E; Ofori-Anyinam O; Vekemans J; Chimpeni P; Lievens M; Wilson TP; Njiram'madzi J; Mendoza YG; Leach A
    Pediatr Infect Dis J; 2018 May; 37(5):483-491. PubMed ID: 29432383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Advanced Development Pathway of the RTS,S/AS01 Vaccine.
    von Seidlein L
    Methods Mol Biol; 2019; 2013():177-187. PubMed ID: 31267502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake.
    Hoyt J; Okello G; Bange T; Kariuki S; Jalloh MF; Webster J; Hill J
    BMC Public Health; 2023 Nov; 23(1):2283. PubMed ID: 37980467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon.
    Lell B; Agnandji S; von Glasenapp I; Haertle S; Oyakhiromen S; Issifou S; Vekemans J; Leach A; Lievens M; Dubois MC; Demoitie MA; Carter T; Villafana T; Ballou WR; Cohen J; Kremsner PG
    PLoS One; 2009 Oct; 4(10):e7611. PubMed ID: 19859560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries.
    Drakeley C; Abdulla S; Agnandji ST; Fernandes JF; Kremsner P; Lell B; Mewono L; Bache BE; Mihayo MG; Juma O; Tanner M; Tahita MC; Tinto H; Diallo S; Lompo P; D'Alessandro U; Ogutu B; Otieno L; Otieno S; Otieno W; Oyieko J; Asante KP; Dery DB; Adjei G; Adeniji E; Atibilla D; Owusu-Agyei S; Greenwood B; Gesase S; Lusingu J; Mahende C; Mongi R; Segeja M; Adjei S; Agbenyega T; Agyekum A; Ansong D; Bawa JT; Boateng HO; Dandalo L; Escamilla V; Hoffman I; Maenje P; Martinson F; Carter T; Leboulleux D; Kaslow DC; Usuf E; Pirçon JY; Bahmanyar ER
    Malar J; 2017 Oct; 16(1):433. PubMed ID: 29078773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
    Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
    Elife; 2022 Jan; 11():. PubMed ID: 35060479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes.
    Miura K; Jongert E; Deng B; Zhou L; Lusingu JP; Drakeley CJ; Fay MP; Long CA; Vekemans J
    Malar J; 2014 Jul; 13():263. PubMed ID: 25007730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "I would have to sell things in order to get the money": A qualitative exploration of willingness to pay for the RTS,S/AS01 malaria vaccine in the Volta region, Ghana.
    Darkwa S; de Wildt G; Dalaba M; Vidzro E; Ansah EK
    PLoS One; 2022; 17(6):e0268009. PubMed ID: 35675273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of RTS,S/AS01
    Samuels AM; Ansong D; Kariuki SK; Adjei S; Bollaerts A; Ockenhouse C; Westercamp N; Lee CK; Schuerman L; Bii DK; Osei-Tutu L; Oneko M; Lievens M; Attobrah Sarfo MA; Atieno C; Morelle D; Bakari A; Sang T; Jongert E; Kotoh-Mortty MF; Otieno K; Roman F; Buabeng PBY; Ntiamoah Y; Ofori-Anyinam O; Agbenyega T;
    Lancet Infect Dis; 2022 Sep; 22(9):1329-1342. PubMed ID: 35753316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.
    Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J
    BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Malaria Transmission Intensity and Parasitemia during the Three-Dose RTS,S/AS01 Vaccination Series do not Reduce Magnitude of Antibody Response nor Efficacy Against the First Case of Malaria.
    Bell GJ; Gyaase S; Goel V; Adu B; Mensah B; Essone P; Dosoo D; Osei M; Niare K; Wiru K; Brandt K; Emch M; Ghansah A; Asante KP; Mvalo T; Agnandji ST; Juliano JJ; Bailey JA
    Res Sq; 2023 May; ():. PubMed ID: 37292711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of RTS,S/AS02(A) and RTS,S/AS01(B) on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial.
    Waitumbi JN; Anyona SB; Hunja CW; Kifude CM; Polhemus ME; Walsh DS; Ockenhouse CF; Heppner DG; Leach A; Lievens M; Ballou WR; Cohen JD; Sutherland CJ
    PLoS One; 2009 Nov; 4(11):e7849. PubMed ID: 19924281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
    Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
    PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RTS,S/AS01
    Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
    Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.